Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Noninferiority of antibody response to human papillomavirus type 16 in subjects vaccinated with monovalent and quadrivalent L1 virus-like particle vaccines.

Literature DB >> 17428949

Noninferiority of antibody response to human papillomavirus type 16 in subjects vaccinated with monovalent and quadrivalent L1 virus-like particle vaccines.

Suzanne M Garland¹, Marc Steben, Mauricio Hernandez-Avila, Laura A Koutsky, Cosette M Wheeler, Gonzalo Perez, Diane M Harper, Sepp Leodolter, Grace W K Tang, Daron G Ferris, Mark T Esser, Scott C Vuocolo, Micki Nelson, Radha Railkar, Carlos Sattler, Eliav Barr.

Abstract

The incorporation of multiple antigens into a single human papillomavirus (HPV) vaccine may induce immune interference. To evaluate whether interference occurs when HPV type 16 (HPV16) virus-like particles are combined in a multivalent vaccine, we conducted a study to evaluate anti-HPV16 responses among subjects receiving three-dose regimens of either a monovalent HPV16 vaccine or a quadrivalent HPV (types 6, 11, 16, and 18) vaccine.

Entities: Species

Mesh：

Substances：

Year: 2007 PMID： 17428949 PMCID： PMC1951095 DOI： 10.1128/CVI.00478-06

Source DB: PubMed Journal: Clin Vaccine Immunol ISSN： 1556-679X

10 in total

Review 1. Estimates of the incidence and prevalence of sexually transmitted diseases in the United States. American Social Health Association Panel.

Authors: W Cates
Journal: Sex Transm Dis Date: 1999-04 Impact factor: 2.830

2. Human papillomavirus is a necessary cause of invasive cervical cancer worldwide.

Authors: J M Walboomers; M V Jacobs; M M Manos; F X Bosch; J A Kummer; K V Shah; P J Snijders; J Peto; C J Meijer; N Muñoz
Journal: J Pathol Date: 1999-09 Impact factor: 7.996

Review 3. Combination vaccines consisting of acellular pertussis vaccines.

Authors: K M Edwards; M D Decker
Journal: Pediatr Infect Dis J Date: 1997-04 Impact factor: 2.129

4. Optimization and validation of a multiplexed luminex assay to quantify antibodies to neutralizing epitopes on human papillomaviruses 6, 11, 16, and 18.

Authors: Dennis Dias; Jeff Van Doren; Sonela Schlottmann; Sheri Kelly; Derek Puchalski; Wanda Ruiz; Patricia Boerckel; Joseph Kessler; Joseph M Antonello; Tina Green; Martha Brown; Judith Smith; Narendra Chirmule; Eliav Barr; Kathrin U Jansen; Mark T Esser
Journal: Clin Diagn Lab Immunol Date: 2005-08

5. Comparative analysis of two rates.

Authors: O Miettinen; M Nurminen
Journal: Stat Med Date: 1985 Apr-Jun Impact factor: 2.373

6. Prophylactic quadrivalent human papillomavirus (types 6, 11, 16, and 18) L1 virus-like particle vaccine in young women: a randomised double-blind placebo-controlled multicentre phase II efficacy trial.

Authors: Luisa L Villa; Ronaldo L R Costa; Carlos A Petta; Rosires P Andrade; Kevin A Ault; Anna R Giuliano; Cosette M Wheeler; Laura A Koutsky; Christian Malm; Matti Lehtinen; Finn Egil Skjeldestad; Sven-Eric Olsson; Margareta Steinwall; Darron R Brown; Robert J Kurman; Brigitte M Ronnett; Mark H Stoler; Alex Ferenczy; Diane M Harper; Gretchen M Tamms; Jimmy Yu; Lisa Lupinacci; Radha Railkar; Frank J Taddeo; Kathrin U Jansen; Mark T Esser; Heather L Sings; Alfred J Saah; Eliav Barr
Journal: Lancet Oncol Date: 2005-05 Impact factor: 41.316

7. Reduced immunogenicity of diphtheria and tetanus toxoids when combined with pertussis toxoid.

Authors: Birger Trollfors; John Taranger; Teresa Lagergård; Valter Sundh
Journal: Pediatr Infect Dis J Date: 2005-01 Impact factor: 2.129

8. Epidemiologic classification of human papillomavirus types associated with cervical cancer.

Authors: Nubia Muñoz; F Xavier Bosch; Silvia de Sanjosé; Rolando Herrero; Xavier Castellsagué; Keerti V Shah; Peter J F Snijders; Chris J L M Meijer
Journal: N Engl J Med Date: 2003-02-06 Impact factor: 91.245

9. Quadrivalent vaccine against human papillomavirus to prevent anogenital diseases.

Authors: Suzanne M Garland; Mauricio Hernandez-Avila; Cosette M Wheeler; Gonzalo Perez; Diane M Harper; Sepp Leodolter; Grace W K Tang; Daron G Ferris; Marc Steben; Janine Bryan; Frank J Taddeo; Radha Railkar; Mark T Esser; Heather L Sings; Micki Nelson; John Boslego; Carlos Sattler; Eliav Barr; Laura A Koutsky
Journal: N Engl J Med Date: 2007-05-10 Impact factor: 91.245

10. Glycoprotein-D-adjuvant vaccine to prevent genital herpes.

Authors: Lawrence R Stanberry; Spotswood L Spruance; Anthony L Cunningham; David I Bernstein; Adrian Mindel; Stephen Sacks; Stephen Tyring; Fred Y Aoki; Moncef Slaoui; Martine Denis; Pierre Vandepapeliere; Gary Dubin
Journal: N Engl J Med Date: 2002-11-21 Impact factor: 91.245

10 in total

15 in total

1. [Nobel price for vaccination against cervical cancer: current data and guidelines].

Authors: H M Hepburn; A M Kaufmann
Journal: Internist (Berl) Date: 2009-05 Impact factor: 0.743

Review 2. Quadrivalent human papillomavirus (types 6, 11, 16, 18) recombinant vaccine (Gardasil®): a review of its use in the prevention of premalignant genital lesions, genital cancer and genital warts in women.

Authors: Paul L McCormack; Elmar A Joura
Journal: Drugs Date: 2010-12-24 Impact factor: 9.546

Review 3. Human papillomavirus vaccines: current status and future prospects.

Authors: Suzanne M Garland; Jennifer S Smith
Journal: Drugs Date: 2010-06-18 Impact factor: 9.546

4. Minor Capsid Protein L2 Polytope Induces Broad Protection against Oncogenic and Mucosal Human Papillomaviruses.

Authors: Somayeh Pouyanfard; Gloria Spagnoli; Lorenzo Bulli; Kathrin Balz; Fan Yang; Caroline Odenwald; Hanna Seitz; Filipe C Mariz; Angelo Bolchi; Simone Ottonello; Martin Müller
Journal: J Virol Date: 2018-01-30 Impact factor: 5.103

5. Alphavirus-adjuvanted norovirus-like particle vaccines: heterologous, humoral, and mucosal immune responses protect against murine norovirus challenge.

Authors: Anna D LoBue; Joseph M Thompson; Lisa Lindesmith; Robert E Johnston; Ralph S Baric
Journal: J Virol Date: 2009-01-28 Impact factor: 5.103

9. Prevalence of human papillomavirus types 6, 11, 16 and 18 in young Austrian women - baseline data of a phase III vaccine trial.

Authors: Lucia Six; Sepp Leodolter; Heather L Sings; Eliav Barr; Richard Haupt; Elmar A Joura
Journal: Wien Klin Wochenschr Date: 2008 Impact factor: 1.704

Review 10. Quadrivalent human papillomavirus (types 6, 11, 16, 18) recombinant vaccine (gardasil(®)): a review of its use in the prevention of premalignant anogenital lesions, cervical and anal cancers, and genital warts.

Authors: Paul L McCormack
Journal: Drugs Date: 2014-07 Impact factor: 11.431